Teva Getting Its First non-Israeli CEO as Shlomo Yanai Resigns

One big challenge incoming chief executive Jeremy Levin faces is to wean the generic drugs giant off Copaxone.

Yoram Gabison
Yoram Gabison
Send in e-mailSend in e-mail

Comments